Glassia

A medical treatment designed for adults with lung disease caused by severe Alpha-1 antitrypsin deficiency, this therapy functions to elevate the levels of the protective Alpha-1 protein in the bloodstream and lung tissue, thereby helping to manage symptoms such as emphysema. Its main features include multiple infusion setting options — including self-infusion at home, administration with a healthcare nurse, or at infusion centers — and various vial sizes (including larger 4- and 5-gram vials) that simplify the infusion process, especially for patients requiring higher doses; it also offers support programs to assist patients with insurance, training, and medication access. This therapy addresses the problem of deficient Alpha-1 protein production, which leaves individuals vulnerable to progressive lung tissue.

Glassia can be found in Lead Enrichment Software categories.